(Q41574335)

4 October 2017

1 reference

title

Digitalis Investigation Group (DIG) trial: a stimulus for further research (English)

1 reference

4 October 2017

Gheorghiade M

1

1 reference

PubMed ID

9266777

4 October 2017

Pitt B

series ordinal

2

1 reference

PubMed ID

9266777

4 October 2017

language of work or name

English

0 references

publication date

1 July 1997

1 reference

4 October 2017

American Heart Journal

1 reference

4 October 2017

134

1 reference

4 October 2017

1

1 reference

4 October 2017

3-12

1 reference

Digitalis--a new controversy regarding an old drug. The pitfalls of inappropriate methods.

4 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Need for a large randomized trial to evaluate the effects of digitalis on morbidity and mortality in congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

The effect of digoxin on mortality and morbidity in patients with heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Heart failure in outpatients: a randomized trial of digoxin versus placebo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

A controlled trial of digoxin in congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

The development of positive inotropic agents for chronic heart failure: how have we gone astray?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Long-term predictors of sudden and low output death in chronic congestive heart failure secondary to coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Relation between plasma norepinephrine and response to medical therapy in men with congestive heart failure secondary to coronary artery disease or idiopathic dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

The chronic effects of long-term digoxin administration on Na+/K(+)-ATPase activity in rat tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

STUDIES ON DIGITALIS. IV. OBSERVATIONS IN MAN ON THE EFFECTS OF DIGITALIS PREPARATIONS ON THE CONTRACTILITY OF THE NON-FAILING HEART AND ON TOTAL VASCULAR RESISTANCE.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Extracardiac and coronary vascular effects of digitalis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Acute effects of digoxin on total systemic vascular resistance in congestive heart failure due to dilated cardiomyopathy: a hemodynamic-hormonal study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Comparative hemodynamic and neurohormonal effects of intravenous captopril and digoxin and their combinations in patients with severe heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Hemodynamic effects of intravenous digoxin in patients with severe heart failure initially treated with diuretics and vasodilators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Influence of digitalis on left ventricular functional response to exercise in congestive heart failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Long-term digitalis therapy improves left ventricular function in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

No upregulation of digitalis glycoside receptor (Na,K-ATPase) concentration in human heart left ventricle samples obtained at necropsy after long term digitalisation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Comparison of effects of dobutamine and ouabain on left ventricular contraction and relaxation in closed-chest dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Effects of acute k-strophantidin administration on left ventricular relaxation and filling phase in coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Effects of ouabain on coronary and systemic vascular resistance and myocardial oxygen consumption in patients without heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Digitalis and the autonomic nervous system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Cellular electrophysiology of digitalis toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

The effect of different digoxin doses on subjective symptoms and physical working capacity in patients with atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Digoxin. A neurohormonal modulator in heart failure?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Effect of long-term digoxin therapy on autonomic function in patients with chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Heart rate variability in patients with mild to moderate heart failure: effects of neurohormonal modulation by digoxin and ibopamine. The Dutch Ibopamine Multicenter Trial (DIMT) Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Digoxin reduces cardiac sympathetic activity in severe congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Effects of increasing maintenance dose of digoxin on left ventricular function and neurohormones in patients with chronic heart failure treated with diuretics and angiotensin-converting enzyme inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Dose-response relationships and plasma concentrations of digitalis glycosides in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Clinical use of serum digoxin concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Dose-response relation between therapeutic levels of serum digoxin and systolic time intervals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Part I Digitalis glycosides: Mechanisms and manifestations of toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Natural history and patterns of current practice in heart failure. The Studies of Left Ventricular Dysfunction (SOLVD) Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Effects of a cardiac glycoside on regional function, blood flow, and electrograms in conscious dogs with myocardial ischemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Susceptibility of infarcted canine hearts to digitalis-toxic ventricular tachycardia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Myocardial infarction following coronary ligation in dogs. Hemodynamic effects of isoproterenol and acetylstrophanthidin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Factors influencing infarct size following experimental coronary artery occlusions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Effects of digitalis on subendocardial and subepicardial dysfunction during acute ischemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Neurogenic coronary vasoconstrictor effects of digitalis during acute global ischemia in dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Ischemia-induced alterations in myocardial (Na+ + K+)-ATPase and cardiac glycoside binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Contractions of canine vascular smooth muscle cells caused by ouabain are due to release of norepinephrine from adrenergic nerve endings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Possible contribution of digitalis-induced coronary constriction to toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Effects of a Digitalis Glycoside on Coronary and Systemic Dynamics in Conscious Dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Vasoconstriction induced by ouabain in the canine coronary artery: contribution of adrenergic and nonadrenergic responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Control of arteriolar resistance in heart failure. Partial attenuation of specific phosphodiesterase inhibitor-mediated vasodilation by digitalis glycosides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Neurally mediated and direct effects of acetylstrophanthidin on canine skeletal muscle vascular resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Prolonged duration of myocardial ischemia in patients with coronary heart disease and impaired cardiopulmonary baroreceptor sensitivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Effect of digitalis treatment on survival after acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Digitalis-associated cardiac mortality after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

The effects of digitalis on survival in high-risk patients with coronary artery disease. The Coronary Artery Surgery Study (CASS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Digitalis and myocardial infarction in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Digoxin therapy and mortality after myocardial infarction. Experience in the MILIS Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Is it safe to prescribe digoxin after acute myocardial infarction? Update on continued controversy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Digoxin and mortality in survivors of acute myocardial infarction: observations in patients at low and intermediate risk. The SPRINT Study Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Association of digitalis therapy with mortality in survivors of acute myocardial infarction: observations in the Beta-Blocker Heart Attack Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Prognostic importance of digitalis after acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Effect of a Digitalis Drug on Ventricular Premature Beats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Enhancement of triggered activity in ischemic Purkinje fibers by ouabain: a mechanism of increased susceptibility to digitalis toxicity in myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Interaction of ischemia and reperfusion with subtoxic concentrations of acetylstrophanthidin in isolated cardiac ventricular tissues: effects on mechanisms of arrhythmia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Autonomic nervous system and sudden cardiac death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Influence of the sympathetic nervous system on the response of the normal heart to digitalis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Effect of quinidine on digoxin bioavailability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Effect of quinidine on digoxin concentration in skeletal muscle and serum in patients with atrial fibrillation. Evidence for reduced binding of digoxin in muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Quinidine-digoxin interaction: Pharmacokinetics, underlying mechanism and clinical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Digoxin-quinidine interaction Pharmacokinetic evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Effects of verapamil on pharmacokinetics and pharmacodynamics of digitoxin in patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Amiodarone increases plasma digoxin concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Clarithromycin-related toxic effects of digoxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Inactivation of Digoxin by the Gut Flora: Reversal by Antibiotic Therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

The hibernating myocardium: implications for management of congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Facilitation of lethal ventricular arrhythmias by therapeutic digoxin in conscious post infarction dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Reduction in digitalis-associated postinfarction mortality with nadolol in conscious dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Ouabain-induced tachyarrhythmias and cell damage in isolated perfused guinea-pig hearts: I. Protection by propranolol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Alteration of ouabain taxicity by cardiac denervation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Beta-blockers and sudden cardiac death.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Mechanism of prevention of sudden death by nadolol: differential actions on arrhythmia triggers and substrate after myocardial infarction in the dog

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Beta-adrenergic blockers and survival in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Cardioprotective effects of carvedilol, a novel beta adrenoceptor antagonist with vasodilating properties, in anaesthetised minipigs: comparison with propranolol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Calcium channel antagonist effects of spironolactone, an aldosterone antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Digoxin enhances the pressor response to aldosterone administration in conscious sheep

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

End of the oldest controversy in medicine. Are we ready to conclude the debate on digitalis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2897%2970100-5

10.1016/S0002-8703(97)70100-5

7 January 2021

Identifiers

DOI

1 reference

4 October 2017

1 reference

PubMed ID

9266777